Biphasic Ketogenic Intervention Protocol

Target: HMGCS2 Composite Score: 0.773 Price: $0.71▲9.7% Citation Quality: Pending metabolic neuroscience Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
✓ All Quality Gates Passed
Quality Report Card click to collapse
B+
Composite: 0.773
Top 14% of 984 hypotheses
T2 Supported
Literature-backed with debate validation
Needs convergence ≥0.40 (current: 0.00) for Established
B+ Mech. Plausibility 15% 0.70 Top 44%
C+ Evidence Strength 15% 0.50 Top 67%
A Novelty 12% 0.80 Top 31%
B Feasibility 12% 0.60 Top 45%
A Impact 12% 0.80 Top 25%
D Druggability 10% 0.30 Top 88%
C Safety Profile 8% 0.40 Top 81%
B+ Competition 6% 0.70 Top 42%
B Data Availability 5% 0.60 Top 51%
B+ Reproducibility 5% 0.70 Top 30%
Evidence
3 supporting | 2 opposing
Citation quality: 0%
Debates
1 session A
Avg quality: 0.80
Convergence
0.00 F 3 related hypothesis share this target

From Analysis:

What determines the optimal timing and dosing of ketogenic interventions for neuroprotection?

While ketone metabolism was discussed as therapeutic, the debate revealed no clear framework for when and how much ketosis provides benefit vs harm. The 'metabolic steal syndrome' hypothesis suggests timing could be critical but remains untested. Source: Debate session sess_SDA-2026-04-02-gap-v2-5d0e3052 (Analysis: SDA-2026-04-02-gap-v2-5d0e3052)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (7)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Epigenetic Priming Ketone Protocol
Score: 0.882 | Target: HDAC2/HDAC3
Astrocyte-Neuron Metabolic Coupling Titration
Score: 0.704 | Target: BDH1
Inflammatory State-Dependent Ketone Timing
Score: 0.647 | Target: IRAKM
Circadian-Gated Ketone Window Hypothesis
Score: 0.606 | Target: OXCT1
Circadian Epigenetic Ketone Synchronization Protocol
Score: 0.543 | Target: CLOCK/BMAL1
Glucose-Ketone Metabolic Switch Timing
Score: 0.531 | Target: GLUT1/GLUT3/MCT1/MCT2
Age-Stratified Ketone Dosing Matrix
Score: 0.452 | Target: OXCT1

→ View full analysis & all 8 hypotheses

Description

Initial high-dose ketone administration (3–5 mM β-hydroxybutyrate) during acute neurological insult may provide immediate mitochondrial support and oxidative stress reduction, consistent with evidence that β-hydroxybutyrate reduces infarct size in stroke models (pmid:40219805) and exhibits anti-aging metabolite properties through multiple cellular pathways (pmid:34684426). This is followed by sustained low-dose maintenance (0.5–1.5 mM) to prevent chronic metabolic dysregulation while maintaining neuroprotective signaling pathways. Evidence suggests ketone bodies confer intrinsic neuroprotection through differential metabolic handling (pmid:32304750).

...

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.70 (15%) Evidence 0.50 (15%) Novelty 0.80 (12%) Feasibility 0.60 (12%) Impact 0.80 (12%) Druggability 0.30 (10%) Safety 0.40 (8%) Competition 0.70 (6%) Data Avail. 0.60 (5%) Reproducible 0.70 (5%) 0.773 composite
5 citations 5 with PMID Validation: 0% 3 supporting / 2 opposing
For (3)
No supporting evidence
No opposing evidence
(2) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
MECH 5CLIN 0GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
β-hydroxybutyrate provides cerebroprotection in st…SupportingMECH----PMID:40219805-
Demonstrates anti-aging metabolite properties thro…SupportingMECH----PMID:34684426-
Differential glucose and ketone metabolism confers…SupportingMECH----PMID:32304750-
High concentrations may have hepatic effects that …OpposingMECH----PMID:36297110-
Not Just an Alternative Energy Source: Diverse Bio…OpposingMECHBiomolecules-2025-PMID:40305364-
Legacy Card View — expandable citation cards

Supporting Evidence 3

β-hydroxybutyrate provides cerebroprotection in stroke models by reducing infarct size
Demonstrates anti-aging metabolite properties through multiple cellular pathways
Differential glucose and ketone metabolism confers intrinsic neuroprotection in immature brains

Opposing Evidence 2

High concentrations may have hepatic effects that weren't considered in the neuroprotection context
Not Just an Alternative Energy Source: Diverse Biological Functions of Ketone Bodies and Relevance of HMGCS2 t…
Not Just an Alternative Energy Source: Diverse Biological Functions of Ketone Bodies and Relevance of HMGCS2 to Health and Disease.
Biomolecules · 2025 · PMID:40305364
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-03 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Based on my research into ketone metabolism, neuroprotection, and the metabolic steal syndrome hypothesis, I'll generate novel therapeutic hypotheses for optimal timing and dosing of ketogenic interventions.

Novel Therapeutic Hypotheses for Ketogenic Neuroprotection

1. Circadian-Gated Ketone Window Hypothesis

Description: Ketone body utilization efficiency follows circadian rhythms, with optimal neuroprotective windows occurring during natural fasting periods (18:00-06:00). β-hydroxybutyrate administered during these periods maximizes mitochondrial efficiency while minimizing

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Based on my analysis of the available research, here is my critical evaluation of each hypothesis:

Critical Analysis of Ketogenic Neuroprotection Hypotheses

1. Circadian-Gated Ketone Window Hypothesis

Specific Weaknesses:

  • The PMID:17126577 citation is vague and doesn't specifically support circadian variations in OXCT1 expression or ketone utilization efficiency
  • No direct evidence provided for the claimed 18:00-06:00 optimal window
  • Assumption that circadian energy metabolism variations translate to ketone-specific therapeutic windows is unsubstantiated

**Counter-Eviden

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Druggability Assessment for Ketogenic Neuroprotection Hypotheses

Based on my analysis of the target proteins and therapeutic landscape, here's a comprehensive assessment of the practical feasibility for each surviving hypothesis:

1. Circadian-Gated Ketone Window Hypothesis (Target: OXCT1)

Revised Confidence: 0.35

Druggability Assessment

POOR DRUGGABILITY - OXCT1 is a mitochondrial matrix enzyme that catalyzes CoA transfer reactions. The active site is highly conserved and essential for cellular metabolism, making selective modulation extremely challenging without disrupting

Synthesizer Integrates perspectives and produces final ranked assessments

Price History

0.570.680.78 debate: market_dynamics (2026-04-16T20:49)debate: market_dynamics (2026-04-16T23:16)evidence: market_dynamics (2026-04-16T23:30)score_update: market_dynamics (2026-04-17T02:21)debate: market_dynamics (2026-04-17T03:05)evidence: market_dynamics (2026-04-17T03:49)evidence: market_dynamics (2026-04-17T04:12)score_update: market_dynamics (2026-04-17T04:59)score_update: market_dynamics (2026-04-17T05:54) 0.89 0.46 2026-04-162026-04-172026-04-22 Market PriceScoreevidencedebate 52 events
7d Trend
Stable
7d Momentum
▼ 13.8%
Volatility
Low
0.0179
Events (7d)
52
⚡ Price Movement Log Recent 9 events
Event Price Change Source Time
📊 Score Update $0.693 ▼ 13.3% market_dynamics 2026-04-17 05:54
📊 Score Update $0.799 ▲ 9.1% market_dynamics 2026-04-17 04:59
📄 New Evidence $0.732 ▲ 25.4% market_dynamics 2026-04-17 04:12
📄 New Evidence $0.584 ▼ 18.9% market_dynamics 2026-04-17 03:49
💬 Debate Round $0.720 ▲ 13.1% market_dynamics 2026-04-17 03:05
📊 Score Update $0.637 ▼ 6.4% market_dynamics 2026-04-17 02:21
📄 New Evidence $0.680 ▲ 16.5% market_dynamics 2026-04-16 23:30
💬 Debate Round $0.584 ▼ 28.9% market_dynamics 2026-04-16 23:16
💬 Debate Round $0.821 market_dynamics 2026-04-16 20:49

Clinical Trials (1)

0
Active
0
Completed
0
Total Enrolled
Untitled Trial Unknown
Unknown ·

📚 Cited Papers (5)

Differential glucose and beta-hydroxybutyrate metabolism confers an intrinsic neuroprotection to the immature brain in a rat model of neonatal hypoxia ischemia.
Experimental neurology (2021) · PMID:32304750
No extracted figures yet
β-hydroxybutyrate as an Anti-Aging Metabolite.
Nutrients (2021) · PMID:34684426
No extracted figures yet
Toxicity Investigations of (R)-3-Hydroxybutyrate Glycerides In Vitro and in Male and Female Rats.
Nutrients (2022) · PMID:36297110
No extracted figures yet
<b>&#x3b2;</b>-hydroxybutyrate enhances brain metabolism in normoglycemia and hyperglycemia, providing cerebroprotection in a mouse stroke model.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (2025) · PMID:40219805
No extracted figures yet
Not Just an Alternative Energy Source: Diverse Biological Functions of Ketone Bodies and Relevance of HMGCS2 to Health and Disease.
Biomolecules (2025) · PMID:40305364
No extracted figures yet

📓 Linked Notebooks (1)

📓 What determines the optimal timing and dosing of ketogenic interventions for neuroprotection? - Analysis Notebook
CI-generated notebook stub for analysis SDA-2026-04-03-gap-debate-20260403-222618-2709aad9. While ketone metabolism was discussed as therapeutic, the debate revealed no clear framework for when and ho …
→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

KG Entities (14)

BDH1GLUT1/GLUT3/MCT1/MCT2HDAC2/HDAC3HMGCS2IRAKMOXCT1h-17a2da3fh-404bab00h-6df1bc66h-9d4571a7h-a1d97415h-a947032ch-d7212534metabolic_neuroscience

Linked Experiments (5)

AECII-specific HMGCS2 overexpression in mouse pulmonary fibrosisvalidation | tests | 0.95Ketogenic diet fat threshold analysis in wild-type micevalidation | tests | 0.90Ketogenic diet efficacy in diet-induced obese micevalidation | tests | 0.90HMGCS2 gain-of-function in AECII lipid metabolism regulationexploratory | tests | 0.90Microarray and single-cell RNA analysis of lipid metabolism genesexploratory | tests | 0.85

Related Hypotheses

Ketone Utilization Index as Metabolic Flexibility Biomarker
Score: 0.819 | translational neuroscience
Temporal Metabolic Window Therapy
Score: 0.644 | neurodegeneration
The Glial Ketone Metabolic Shunt Hypothesis
Score: 0.608 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (13 edges)

associated with (6)

HDAC2/HDAC3 metabolic_neuroscience
HMGCS2 metabolic_neuroscience
BDH1 metabolic_neuroscience
IRAKM metabolic_neuroscience
OXCT1 metabolic_neuroscience
...and 1 more

targets (7)

h-d7212534 HDAC2/HDAC3
h-6df1bc66 HMGCS2
h-17a2da3f BDH1
h-a1d97415 IRAKM
h-9d4571a7 OXCT1
...and 2 more

Mechanism Pathway for HMGCS2

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    h_d7212534["h-d7212534"] -->|targets| HDAC2_HDAC3["HDAC2/HDAC3"]
    h_6df1bc66["h-6df1bc66"] -->|targets| HMGCS2["HMGCS2"]
    h_17a2da3f["h-17a2da3f"] -->|targets| BDH1["BDH1"]
    h_a1d97415["h-a1d97415"] -->|targets| IRAKM["IRAKM"]
    h_9d4571a7["h-9d4571a7"] -->|targets| OXCT1["OXCT1"]
    h_a947032c["h-a947032c"] -->|targets| GLUT1_GLUT3_MCT1_MCT2["GLUT1/GLUT3/MCT1/MCT2"]
    h_404bab00["h-404bab00"] -->|targets| OXCT1_1["OXCT1"]
    HDAC2_HDAC3_2["HDAC2/HDAC3"] -->|associated with| metabolic_neuroscience["metabolic_neuroscience"]
    HMGCS2_3["HMGCS2"] -->|associated with| metabolic_neuroscience_4["metabolic_neuroscience"]
    BDH1_5["BDH1"] -->|associated with| metabolic_neuroscience_6["metabolic_neuroscience"]
    IRAKM_7["IRAKM"] -->|associated with| metabolic_neuroscience_8["metabolic_neuroscience"]
    OXCT1_9["OXCT1"] -->|associated with| metabolic_neuroscience_10["metabolic_neuroscience"]
    style h_d7212534 fill:#4fc3f7,stroke:#333,color:#000
    style HDAC2_HDAC3 fill:#ce93d8,stroke:#333,color:#000
    style h_6df1bc66 fill:#4fc3f7,stroke:#333,color:#000
    style HMGCS2 fill:#ce93d8,stroke:#333,color:#000
    style h_17a2da3f fill:#4fc3f7,stroke:#333,color:#000
    style BDH1 fill:#ce93d8,stroke:#333,color:#000
    style h_a1d97415 fill:#4fc3f7,stroke:#333,color:#000
    style IRAKM fill:#ce93d8,stroke:#333,color:#000
    style h_9d4571a7 fill:#4fc3f7,stroke:#333,color:#000
    style OXCT1 fill:#ce93d8,stroke:#333,color:#000
    style h_a947032c fill:#4fc3f7,stroke:#333,color:#000
    style GLUT1_GLUT3_MCT1_MCT2 fill:#ce93d8,stroke:#333,color:#000
    style h_404bab00 fill:#4fc3f7,stroke:#333,color:#000
    style OXCT1_1 fill:#ce93d8,stroke:#333,color:#000
    style HDAC2_HDAC3_2 fill:#ce93d8,stroke:#333,color:#000
    style metabolic_neuroscience fill:#ef5350,stroke:#333,color:#000
    style HMGCS2_3 fill:#ce93d8,stroke:#333,color:#000
    style metabolic_neuroscience_4 fill:#ef5350,stroke:#333,color:#000
    style BDH1_5 fill:#ce93d8,stroke:#333,color:#000
    style metabolic_neuroscience_6 fill:#ef5350,stroke:#333,color:#000
    style IRAKM_7 fill:#ce93d8,stroke:#333,color:#000
    style metabolic_neuroscience_8 fill:#ef5350,stroke:#333,color:#000
    style OXCT1_9 fill:#ce93d8,stroke:#333,color:#000
    style metabolic_neuroscience_10 fill:#ef5350,stroke:#333,color:#000

3D Protein Structure

🧬 HMGCS2 — PDB 2WYA Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

What determines the optimal timing and dosing of ketogenic interventions for neuroprotection?

metabolic neuroscience | 2026-04-03 | completed

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)